Movement Alert｜Akeso Rises 3.64% in Regular Trading, Industry Buyback Wave and Sector Oversold Rebound Support Price Stabilization

Market Focus06-18

On June 18, Akeso (9926.HK) rose 3.64% in regular trading, trading at HK$88.3 per share, with turnover of HK$273 million.

On the news front, an ongoing wave of share buybacks across the pharmaceutical industry, combined with the innovative drug sector rebounding from historically low valuations, provided dual support for the stock. The company's board previously approved a plan to deploy up to HK$200 million for open-market share purchases, while management proposed additional holdings of up to HK$50 million. These capital signals reflect confidence in the company's intrinsic value.

The stock had declined over 30% from its post-ASCO peak following the release of positive overall survival data from the HARMONi-6 study on June 1, as event-driven funds engaged in sustained profit-taking. Technical oversold conditions and industrial capital commitment are now jointly underpinning the rebound. Notably, over 100 pharmaceutical companies have disclosed buyback or share purchase plans in recent months, forming a sector-wide buyback trend amid valuations near historical lows.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179848973?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 10:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179848973","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Akeso Rises 3.64% in Regular Trading, Industry Buyback Wave and Sector Oversold Rebound Support Price Stabilization","media":"Market Focus","content":"<p><p>On June 18, Akeso (9926.HK) rose 3.64% in regular trading, trading at HK$88.3 per share, with turnover of HK$273 million.</p><p>On the news front, an ongoing wave of share buybacks across the pharmaceutical industry, combined with the innovative drug sector rebounding from historically low valuations, provided dual support for the stock. The company's board previously approved a plan to deploy up to HK$200 million for open-market share purchases, while management proposed additional holdings of up to HK$50 million. These capital signals reflect confidence in the company's intrinsic value.</p><p>The stock had declined over 30% from its post-ASCO peak following the release of positive overall survival data from the HARMONi-6 study on June 1, as event-driven funds engaged in sustained profit-taking. Technical oversold conditions and industrial capital commitment are now jointly underpinning the rebound. Notably, over 100 pharmaceutical companies have disclosed buyback or share purchase plans in recent months, forming a sector-wide buyback trend amid valuations near historical lows.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Rises 3.64% in Regular Trading, Industry Buyback Wave and Sector Oversold Rebound Support Price Stabilization</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Rises 3.64% in Regular Trading, Industry Buyback Wave and Sector Oversold Rebound Support Price Stabilization\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-18 10:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 18, Akeso (9926.HK) rose 3.64% in regular trading, trading at HK$88.3 per share, with turnover of HK$273 million.</p><p>On the news front, an ongoing wave of share buybacks across the pharmaceutical industry, combined with the innovative drug sector rebounding from historically low valuations, provided dual support for the stock. The company's board previously approved a plan to deploy up to HK$200 million for open-market share purchases, while management proposed additional holdings of up to HK$50 million. These capital signals reflect confidence in the company's intrinsic value.</p><p>The stock had declined over 30% from its post-ASCO peak following the release of positive overall survival data from the HARMONi-6 study on June 1, as event-driven funds engaged in sustained profit-taking. Technical oversold conditions and industrial capital commitment are now jointly underpinning the rebound. Notably, over 100 pharmaceutical companies have disclosed buyback or share purchase plans in recent months, forming a sector-wide buyback trend amid valuations near historical lows.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1179848973","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179848973","pubTimestamp":1781748383,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 18, Akeso (9926.HK) rose 3.64% in regular trading, trading at HK$88.3 per share, with turnover of HK$273 million.On the news front, an ongoing wave of share buybacks across the pharmaceutical...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"动向提示|康方生物常规交易涨3.64%行业回购潮及板块超跌反弹支撑价格企稳","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On June 18, Akeso (9926.HK) rose 3.64% in regular trading, trading at HK$88.3 per share, with turnover of HK$273 million.On the news front, an ongoing wave of share buybacks across the pharmaceutical industry, combined with the innovative drug sector rebounding from historically low valuations, provided dual support for the stock. The company's board previously approved a plan to deploy up to HK$200 million for open-market share purchases, while management proposed additional holdings of up to HK$50 million. These capital signals reflect confidence in the company's intrinsic value.The stock had declined over 30% from its post-ASCO peak following the release of positive overall survival data from the HARMONi-6 study on June 1, as event-driven funds engaged in sustained profit-taking. Technical oversold conditions and industrial capital commitment are now jointly underpinning the rebound. Notably, over 100 pharmaceutical companies have disclosed buyback or share purchase plans in recent months, forming a sector-wide buyback trend amid valuations near historical lows.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179848973","isCrawlerRequest":true}